Literature DB >> 3678316

Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent.

L S Capolongo1, G Balconi, P Ubezio, R Giavazzi, G Taraboletti, A Regonesi, O C Yoder, M D'Incalci.   

Abstract

The antiproliferative activity of flavone acetic acid (LM 975) was investigated on human adenocarcinoma cell lines (HCC-P2998, HCC-M1544, HCC-M1410, HT 29, LoVo), on a murine colon adenocarcinoma cell line (Colon 26), on murine pancreatic adenocarcinoma cells growing in primary culture (Pan 03) and on human normal fibroblasts (N1). No cytotoxic effects were found against human normal fibroblasts. LM 975 was active against murine adenocarcinoma Pan 03 and Colon 26, known to be sensitive in vivo too and, to variable extents, on human adenocarcinoma cell lines. LM 975 in vitro cytotoxic potency was relatively low. The high concentrations (1.0-1.4 mM) required to obtain a cytotoxic effect are, however, pharmacologically reasonable since they are comparable with drug plasma levels in mice or in patients treated with tolerable doses. After a relatively short LM 975 treatment (2 h) DNA, RNA and protein synthesis were inhibited in different proportions. In more sensitive cells LM 975 appeared to inhibit RNA synthesis more than DNA and protein synthesis. Inhibition of macromolecule synthesis after 2 h exposure was completely reversed in 24 h recovery. After 2 h treatment no detectable DNA breakage was found by the alkaline elution method, thus corroborating the idea that this compound does not act by causing DNA damage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3678316     DOI: 10.1016/0277-5379(87)90096-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  15 in total

1.  Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.

Authors:  G Damia; G Tagliabue; P Allavena; M D'Incalci
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Flavone acetic acid and plasma protein binding.

Authors:  J Brodfuehrer; F Valeriote; K Chan; L Heilbrun; T Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512).

Authors:  M C Bibby; R M Phillips; J A Double
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.

Authors:  Minh Hien Pham; Hervé Rhinn; Nicolas Auzeil; Anne Regazzetti; Djamel Eddine Harami; Daniel Scherman; Guy G Chabot
Journal:  Drug Metab Lett       Date:  2011-04

Review 6.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours.

Authors:  J Cummings; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.

Authors:  G G Chabot; M C Bissery; A Gouyette
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Flavone acetic acid distribution in human malignant tumors.

Authors:  G Damia; A Freschi; R Sorio; A Braida; G Caruso; M Quaia; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.

Authors:  R Giavazzi; A Garofalo; G Damia; S Garattini; M D'Incalci
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

10.  Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).

Authors:  M C Bibby; J A Double; P M Loadman
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.